Advertisement

Topics

Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa (netarsudil ophthalmic solution) 0.02%

19:05 EDT 15 May 2017 | Drugs.com

IRVINE, Calif.--(BUSINESS WIRE) May 15, 2017 -- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...

Original Article: Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa (netarsudil ophthalmic solution) 0.02%

NEXT ARTICLE

More From BioPortfolio on "Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa (netarsudil ophthalmic solution) 0.02%"

Advertisement
Quick Search
Advertisement
Advertisement